Abstract
Background Allergic asthma is associated with increased risk of respiratory tract infections and exacerbations. It remains unclear whether this susceptibility is conditioned by seasonal or by perennial allergy.
Aim To investigate perennial allergy compared with seasonal allergy as a risk factor for lower respiratory tract infections and exacerbations in asthma and whether this risk can be reduced by allergen immunotherapy (AIT).
Methodology This is a prospective register-based nationwide study of 18–44-year-olds treated with AIT during1995–2014. Based on the type of AIT and use of anti-asthmatic drugs, patients were subdivided into two groups: perennial allergic asthma (PAA) versus seasonal allergic asthma (SAA). Data on antibiotics against lower respiratory tract infections (LRTI) and oral corticosteroids for exacerbations were analyzed before starting AIT (baseline) and three years after completing AIT (follow-up).
Results We identified 2688 patients with asthma treated with AIT, among whom, 1249 had PAA and 1439 had SAA. At baseline, patients with SAA had more exacerbations, 23.8%, respectively, 16.5% p=<0.001 but there were no differences in LRTI. During the three-year follow-up, we observed a highly significant reduction of exacerbations with an average decrease of 57% in PAA and 74% in SAA. We also observed a significant reduction of LRTI in both PAA and SAA: 17% and 20% decrease, respectively.
Conclusion AIT effectively reduced the risk of exacerbations and lower respiratory tract infections in both seasonal- and perennial allergic asthma. Perennial allergy is seemingly not a stronger risk factor for respiratory infections and exacerbations than is seasonal allergy.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interests: An ICMJE Conflict of Interest form has been collected from all authors. Woehlk, C. has received speakers fee from ALK Abelló Nordic A/s. Baastrup, M. report speakers fee from GlaxoSmithKline. Von Bülow, A. has received speakers fee from AstraZeneca, GlaxoSmithKline, and Novartis and has attended advisory board for Novartis and AstraZeneca.
Conflict of interests: Porsbjerg, C. reports; grants or contracts from AstraZeneca, GlaxoSmithKline, Novartis, TEVA, Sanofi, Chesi and ALK Abelló A/s to the institution; consulting fees from AstraZeneca, GlaxoSmithKline, Novartis, TEVA, Sanofi, Chesi and ALK Abelló A/s to the institution and personal honoraria; speakers fee from: AstraZeneca, GlaxoSmithKline, Novartis, TEVA, Sanofi, Chesi and ALK Abelló A/s to the institution and personal honoraria; advisory board honoraria from: AstraZeneca, Novartis, TEVA, Sanofi, and ALK Abelló A/s to the institution and personal honoraria. Ghanizada, M. and Hansen, S. reports no conflicts of interest.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received March 4, 2022.
- Accepted May 10, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org